Protocol Ledger

NCT04629833 · Phase III · RECRUITING

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

Interventional Phase III clinical trial protocol NCT04629833 sponsored by medac in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-16 Enrollment: 210 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04629833
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)210 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04629833
Protocol FieldVerified Registry Value
NCT IdentifierNCT04629833
Consolidated Lead Sponsormedac
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment210 participants (ESTIMATED)
Registered Start Date2021-08-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04629833
Hospital Research SiteLocationSite Profile
Medizinische Hochschule HannoverHanover, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI